

## Molecular-Biological Characteristics of Type I, Ovarian Low-Grade Serous and Mucinous Carcinomas and Prospects of Molecular-Targeted Therapy

Nakayama K\*, Nakamura K, Ishibashi T, Sanuki K, Ishikawa M and Kyo S

Department of Obstetrics and Gynaecology, Shimane University School of Medicine, Shimane, Japan

\*Corresponding author: Kentaro Nakayama, Shimane University School of Medicine, Enyacho 89-1, Izumo, Shimane, Japan, Tel: 81-853-20-2268; Fax: 81-853-20-2264; E-mail: [kn88@med.shimane-u.ac.jp](mailto:kn88@med.shimane-u.ac.jp)

Received date: March 23, 2016; Accepted date: April 11, 2016; Published date: April 14, 2016

Copyright: © 2016 Nakayama K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

### Abstract

Two models of carcinogenesis have recently been proposed for ovarian cancer based on the differences in the mechanism of carcinogenesis. Low-grade serous carcinoma and mucinous carcinoma are classified as type I, and high-grade serous carcinoma and high-grade endometrioid carcinoma are classified as type II ovarian cancers.

Low-and high-grade serous carcinomas were reported to have independent pathologies based on their morphological characteristics, molecular mechanism of histogenesis, and clinical features. Serial activation of the components of the mitogen activated protein kinase (MAPK) signaling pathway was observed in low-grade serous carcinomas resistant to existing anticancer drugs, and the efficacy of MEK inhibitors targeting these signals has been demonstrated. The morphology- and molecular biology-based elucidation of the pathology of ovarian cancers might lead to the implementation of personalized treatment through molecular-targeted therapy.

**Keywords:** Low-grade serous carcinoma; Mucinous carcinoma; Ovarian cancer

### Introduction

Kurman and Shih et al. of Johns Hopkins University, USA, recently proposed a new classification for ovarian cancers based on their morphological characteristics, the presence of precancerous lesions, and molecular-biological characteristics of the tumor [1,2]. Low-grade serous and mucinous carcinomas are classified as type I, and high-grade serous and endometrioid carcinomas are classified as type II ovarian cancers (Figure 1).

Type I ovarian cancers have been reported to progress from benign to borderline malignant tumors and gradually to infiltrating cancers. *KRAS* or *BRAF* are mutated in 65% of low-grade serous carcinoma cases [3]. In contrast, in mucinous carcinomas, the frequency of *KRAS* mutations is high whereas that of *BRAF* mutations is low, and *HER2* amplification is present in approximately 30% of mucinous carcinoma cases [4]. In this report, the clinical and molecular-biological characteristics of low-grade serous and mucinous carcinomas are described and the future prospects for molecular-targeted therapy are outlined.

### Clinical Characteristics of Low-Grade Serous Carcinoma

The onset age for low-grade serous carcinoma is younger than that for high-grade serous carcinoma, showing a high incidence rate in the early 40s [5]. The ratio of low- to high-grade serous carcinoma cases among all serous carcinoma cases is 1:9, indicating a very low incidence of low-grade serous carcinoma [6]. Anticancer drug sensitivity of low-grade serous carcinoma is lower than that of high-grade serous carcinoma [5]; however, the clinical prognosis is more favorable than that of high-grade serous carcinoma [7]. These findings might reflect the biological characteristics of the disease, which is a tumor of low malignant potential. The indications for secondary cytoreductive surgery (SDS) for recurrence are the presence of a solitary lesion or 2 lesions and the possibility of complete removal by surgery. SDS might be indicated for many cases of low-grade serous carcinoma because disease progression is slow and it is resistant to existing chemotherapy regimens [8]. Recently, Gershenson et al. [5] reported that woman aged <35 years with low-grade serous carcinoma and those with persistent disease at the end of therapy have the worst outcomes [9].

### A proposal model of Ovarian carcinogenesis




Figure 1

**Figure 1:** Carcinogenesis model of ovarian cancer. (Figure adapted from [1]).

## Molecular-Biological Characteristics of Low-Grade Serous Carcinoma

Low-grade serous carcinoma is accompanied by a serous borderline tumor as a precancerous lesion, and carcinogenesis is considered to occur through the adenoma-carcinoma sequence [1]. In high-grade serous carcinoma, the *p53* gene mutation is noted at a frequency of almost 100% [10], whereas this mutation is absent in low-grade serous carcinoma [3]. It was reported that in low-grade serous carcinoma, somatic cell mutation of *KRAS/BRAF* (oncogenic mutation) is present in a mutually exclusive manner; abnormality is present in one of these genes at approximately 65% frequency, and the downstream MAPK signal is constitutively activated [11]. We previously reported that a 12 base-pair insertion mutation of *HER2* (ERBB2) occurred in low-grade serous carcinoma without *KRAS/BRAF* mutation at a frequency of 9% [3]. We also discovered that the *KRAS/BRAF* mutation might serve as a biomarker for the efficacy of MEK1/2 inhibitors [12]. In order to investigate the presence of a new oncogene, we performed exome sequencing of low-grade serous carcinoma [13]; however, no new oncogene other than the *KRAS/BRAF* oncogene with mutation was detected [13]. We previously reported a low frequency for gene copy number mutations in low-grade serous carcinoma [14]. We considered the involvement of abnormal microRNAs and the epigenome in carcinoma is (Figure 2).




Figure 2: KRAS/BRAF gene mutation in the ovarian cancer cell line and the effect of the MEK inhibitor. (Figure adapted from [13]).

The results of exome sequencing of serous borderline tumors were recently reported. In addition to the previously reported oncogenic mutations of *BRAF*, *FBXW7*, and *KIAA1462*, novel gene mutations were reported [15]. Research groups from Johns Hopkins University and MD Anderson Cancer Center recently reported 2 new lines of evidence supporting the type I carcinogenesis pathway. Peritoneal implants of serous borderline tumors/atypical proliferative serous tumors, which are considered to be precancerous lesions of low-grade serous carcinoma, had the same *KRAS/BRAF* mutation pattern as that of the primary lesions, suggesting that these are metastatic lesions arising from the primary lesion [16]. In addition, *KRAS* mutation, but not *BRAF* mutation, was involved in the progression of a serous borderline tumor to low-grade serous carcinoma, and *KRAS G12V* mutation indicated poor prognosis [17]. Recently, Emmanuel et al. reported *NRAS* mutations in 9% of invasive serous carcinomas with adjacent serous borderline tumors suggesting *NRAS* as an oncogenic driver in low-grade serous carcinomas [18]. Furthermore, Gershenson et al. [5] reported that patients with *KRAS* or *BRAF* mutations had significantly better overall survival than those with wild type *KRAS* or *BRAF* [19].

## Clinical Characteristics of Mucinous Carcinoma

Many cases of ovarian mucinous carcinoma are clinical stage I or II, and most cases undergo complete surgical resection. Therefore, the prognosis associated with early cases is favorable [20]. In a clinical study reported by the US Gynecologic Oncology Group (GOG), the outcome of clinical stage III epithelial ovarian cancer in patients who received paclitaxel and carboplatin (TC) chemotherapy was the poorest compared to those of other histologic types of mucinous carcinoma [21]. Moreover, anticancer drug sensitivity was low and survival time was short compared to those of high-grade serous carcinoma patients in many reported studies [22,23]. Because this cancer has a low sensitivity to existing TC chemotherapy, a new chemotherapy regimen is being investigated. In 2003, Seidman et al. reported that 77% of pathologically diagnosed mucinous carcinoma cases were metastases from multiple organs, which was very surprising [24].


Based on the concept that mucinous carcinoma is similar to gastrointestinal cancers, such as colorectal and gastric cancers, clinical studies were performed using the chemotherapy regimen for gastrointestinal cancers. The Japan Ovarian Mucinous Adenocarcinoma Study Group performed a phase II study using SOX chemotherapy (S-1, oxaliplatin) for advanced and recurrent mucinous carcinomas. According to its interim report, the central pathological diagnosis was primary mucinous carcinoma in 14 out of 40 patients, and metastatic mucinous carcinoma from primary lesions occurred in the pancreas, stomach, and large intestine of 19 patients, accounting for nearly half of the patients. Seven patients were diagnosed with ovarian cancer rather than with mucinous carcinoma. The diagnosis rate for primary mucinous carcinoma was 35%, indicating difficulty in making a diagnosis, which supports the findings reported by Seidman et al. The response rate of all mucinous carcinoma cases to chemotherapy was 12.1%, and the disease control rate was 69.6%. The response and disease control rates of primary mucinous carcinoma cases were 0 and 64.2%, respectively, and those of metastatic mucinous carcinoma cases were 21 and 73.6%, respectively. It was concluded that approximately 50% of advanced and recurrent ovarian mucinous carcinoma cases were metastatic tumors and that SOX chemotherapy might contribute to the improvement of the overall survival time [25] (Figure 3).

## Molecular-Biological Characteristics of Mucinous Carcinoma

Molecular-biological studies on ovarian mucinous carcinoma concerning histologic types are limited, which is clinically attributable to its low incidence rates (approximately 3-10%). The frequency of *KRAS* gene mutations was 75% [26], and the presence of *KRAS* mutations in mucinous cystadenoma and mucinous borderline tumors, assumed to be precancerous lesions, was reported [27]. Therefore, it was suggested that carcinogenesis occurred through the adenoma-carcinoma sequence over a long period.

The *p53* mutations observed in type II ovarian cancers and *BRAF* mutations observed in low-grade serous carcinoma are absent in mucinous carcinoma [28]. We also previously performed comprehensive allelotype analysis of mucinous and serous borderline tumors [29]. In Japan, the frequency of the mucinous type is very high in borderline tumors (mucinous: serous=5:1), suggesting that the carcinogenesis mechanism of ovarian cancers is different from that in the western population [30]. Deleted regions are distributed

throughout all chromosomes on mucinous borderline tumors, whereas deletions are concentrated on some chromosomes in serous borderline tumors. Based on this, we paid attention to differences in the mechanism of carcinogenesis between the histologic types [29].



It was recently reported that the frequency of *HER2* gene amplifications in mucinous carcinoma was 18.3% among the western population [4] and 35.3% among Asians [31], suggesting that *HER2*-targeting molecular-targeted therapy is effective. Indeed, McAlpine et al. administered trastuzumab in addition to standard chemotherapy to 3 patients with mucinous carcinoma, and observed a marked effect in 1 patient [4]. Currently, we are performing whole exome analysis of mucinous carcinoma as a rare tumor sequence in a cooperative study with Johns Hopkins University, investigating the presence of a new gene aberration.

### Prospects of Molecular Targeting Drugs

We previously reported that *MAPK* signals are constitutively activated in an ovarian cancer cell line possessing *KRAS/BRAF* mutations, and MEK1/2 inhibitor exhibited a marked effect at the cellular level and in a nude mouse transplantation model [12]. A phase II study using selumetinib (AZD6244, ARRY142866), a MEK1/2 inhibitor, was recently conducted by the US (GOG) in patients with recurrent low-grade serous carcinoma [28].

Fifty-two patients were enrolled and continuously received 50 mg of oral selumetinib twice daily until disease progression was observed; 4-week administration was regarded 1 cycle. Interestingly, complete remission (CR) and partial remission (PR) were noted in 1 and 7 patients, respectively, and the response rate was 15.4%. Stable disease (SD) was observed in 34 (65.4%) patients, and the disease control rate was 80.8%. The median aggravation-free survival time was 11.0 months, and a 6-month or longer aggravation-free period was achieved in 63.5% (33/52) of patients. No death related to adverse events was reported. Unfortunately, no correlation was noted between the *KRAS/BRAF* mutation and response rate, and the diagnostic value of the *KRAS/BRAF* mutation remains unclear [32]. No clinical study of a molecular-targeted drug for mucinous carcinoma has been reported;

however, molecular-biologically, a therapeutic strategy using MEK1/2 inhibitors might be possible, similar to that for low-grade serous carcinoma, because of the high *KRAS*- and low *p53*-mutation rates. Treatment with trastuzumab is also expected because the frequency of human epidermal growth factor receptor (*HER*) 2 gene amplification is high in mucinous carcinoma [4].

### Conclusion

Both low-grade serous carcinoma and mucinous carcinoma are low sensitive to existing anticancer drugs, causing problems for clinicians. They have not been widely studied due to low incidence rates. However, with recent advances in molecular biology, the efficacy of *KRAS/BRAF/MAPK* signal-targeted treatment was shown in a preclinical study and the efficacy of selumetinib (AZD6244, ARRY142866), a MEK1/2 inhibitor, was shown in a phase II clinical study. Carcinogenesis mechanism-based personalized treatment might improve the outcome in the future.

We are now attempting to establish immortalized ovarian serous cystadenoma and mucinous adenoma cells, and the construction of an *in vitro* carcinogenesis model for type I ovarian cancer pathway is underway. This carcinogenesis model is expected to provide a basis for the development of molecular-targeted therapies of low-grade serous carcinoma and mucinous carcinoma.

### References

1. Cho KR, Shih IeM (2009) Ovarian cancer. *Annu Rev Pathol* 4: 287-313.
2. Kurman RJ, Shih IeM (2016) The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded. *Am J Pathol* 186: 733-747.
3. Nakayama K, Nakayama N, Kurman RJ, Cope L, Pohl G, et al. (2006) Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. *Cancer Biol Ther* 5: 779-785.
4. McAlpine JN, Wiegand KC, Vang R, Ronnett BM, Adamiak A, et al. (2009) *HER2* overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. *BMC Cancer* 9: 433.
5. Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, et al. (2009) Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. *Gynecol Oncol* 114: 48-52.
6. Singer G, Stohr R, Cope L, Dehari R, Hartmann A, et al. (2005) Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. *Am J Surg Pathol* 29: 218-224.
7. Motohara T, Tashiro H, Miyahara Y, Sakaguchi I, Ohtake H, et al. (2010) Long-term oncological outcomes of ovarian serous carcinomas with psammoma bodies: a novel insight into the molecular pathogenesis of ovarian epithelial carcinoma. *Cancer Sci* 101: 1550-1556.
8. Bristow RE, Gossett DR, Shook DR, Zahurak ML, Tomacruz RS, et al. (2002) Recurrent micropapillary serous ovarian carcinoma. *Cancer* 95: 791-800.
9. Gershenson DM, Bodurka DC, Lu KH, Nathan LC, Milojevic L, et al. (2015) Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor. *Journal of clinical oncology* 33: 2675-2682.
10. Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. *Nature* 474: 609-615.
11. Hsu CY, Bristow R, Cha MS, Wang BG, Ho CL, et al. (2004) Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. *Clin Cancer Res* 10: 6432-6436.

12. Nakayama N, Nakayama K, Yeasmin S, Ishibashi M, Katagiri A, et al. (2008) *KRAS* or *BRAF* mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. *Br J Cancer* 99: 2020-2028.
13. Jones S, Wang TL, Kurman RJ, Nakayama K, Velculescu VE, et al. (2012) Low-grade serous carcinomas of the ovary contain very few point mutations. *J Pathol* 226: 413-420.
14. Nakayama K, Nakayama N, Jinawath N, Salani R, Kurman RJ, et al. (2007) Amplicon profiles in ovarian serous carcinomas. *Int J Cancer* 120: 2613-2617.
15. Boyd J, Luo B, Peri S, Wirchansky B, Hughes L, et al. (2013) Whole exome sequence analysis of serous borderline tumors of the ovary. *Gynecol Oncol* 130: 560-564.
16. Ardighieri L, Zeppernick F, Hannibal CG, Vang R, Cope L, et al. (2014) Mutational analysis of *BRAF* and *KRAS* in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants. *J Pathol* 232: 16-22.
17. Tsang Y, Deavers MT, Sun CC, Kwan SY, Kuo E, et al. (2013) *KRAS* (but not *BRAF*) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma. *J Pathol* 231: 449-456.
18. Emmanuel C, Chiew YE, George J, Etemadmoghadam D, Anglesio MS, et al. (2014) Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies *NRAS* as an oncogenic driver. *Clin Cancer Res* 20: 6618-6630.
19. Gershenson DM, Sun CC, Wong KK (2015) Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum. *Br J Cancer* 113: 1254-1258.
20. Malkasian GD Jr, Melton LJ 3rd, O'Brien PC, Greene MH (1984) Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary. *Am J Obstet Gynecol* 149: 274-284.
21. Winter WE 3rd, Maxwell GL, Tian C, Carlson JW, Ozols RF, et al. (2007) Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. *J Clin Oncol* 25: 3621-3627.
22. Hess V, A'Hern R, Nasiri N, King DM, Blake PR, et al. (2004) Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. *J Clin Oncol* 22: 1040-1044.
23. Shimada M, Kigawa J, Ohishi Y, Yasuda M, Suzuki M, et al. (2009) Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. *Gynecol Oncol* 113: 331-334.
24. Seidman JD, Kurman RJ, Ronnett BM (2003) Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. *Am J Surg Pathol* 27: 985-993.
25. Shimada M, Nishio S, Islitani K (2013) Phase II study of SOX therapy in recurrent ovarian mucinous carcinoma. *Acta Obstetrica Gynecologica Japonica* 65: 685.
26. Enomoto T, Weghorst CM, Inoue M, Tanizawa O, Rice JM (1991) K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. *Am J Pathol* 139: 777-785.
27. Mandai M, Konishi I, Kuroda H, Komatsu T, Yamamoto S (1998) Heterogeneous distribution of K-ras-mutated epithelia in mucinous ovarian tumors with special reference to histopathology. *Hum Pathol* 29: 34-40.
28. Rahman M, Nakayama K, Rahman MT, Nakayama N, Katagiri H, et al. (2013) PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes. *Anticancer Res* 33: 113-118.
29. Nakayama K, Takebayashi Y, Namiki T, Tamahashi N, Nakayama S (2001) Comprehensive allelotyping study of ovarian tumors of low malignant potential: potential differences in pathways between tumors with and without genetic predisposition to invasive carcinoma. *International Journal of Cancer* 94: 605-609.
30. Fukumoto M, Nakayama K (2006) Ovarian epithelial tumors of low malignant potential: are they precursors of ovarian carcinoma? *Pathol Int* 56: 233-239.
31. Chay WY, Chew SH, Ong WS, Busmanis I, Li X, et al. (2013) *HER2* amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer. *PloS One* 8: e61565.
32. Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, et al. (2013) Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. *Lancet Oncol* 14: 134-140.